What do systematic reviews say?

Residual disease (RD) > 0 cm vs NMRD

It is very uncertain whether residual disease (RD) > 0 cm changes progression‐free survival: Median length of compared with NMRD (very low certainty).

• Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after… 2022 · Cochrane Headline outcomes only
  HR 1.36 [1.05, 1.76]
  1 study · 471 participants
  Very low

Small‐volume residual disease (SVRD) (< 1 cm) vs NMRD

Small‐volume residual disease (SVRD) < 1 cm probably leads to higher progression‐free survival: Median length of compared with NMRD (moderate certainty).

• Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after… 2022 · Cochrane Headline outcomes only
  HR 1.88 [1.63, 2.16]
  10 studies · 6596 participants
  Moderate

Large‐volume residual disease (LVRD) > 1 cm vs NMRD

Large‐volume residual disease (LVRD) > 1 cm probably leads to higher overall survival: Median length of compared with no macroscopic residual disease (NMRD) (moderate certainty).

• Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after… 2022 · Cochrane Headline outcomes only
  HR 2.5 [2.13, 2.94]
  14 studies · 7988 participants
  Moderate

Large‐volume residual disease (LVRD) > 1 cm vs NMRD

Large‐volume residual disease (LVRD) > 1 cm probably leads to higher progression‐free survival: Median length of compared with no macroscopic residual disease (NMRD) (moderate certainty).

• Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after… 2022 · Cochrane Headline outcomes only
  HR 2.1 [1.84, 2.4]
  6 studies · 2629 participants
  Moderate

Large‐volume residual disease (LVRD) > 1 cm vs small‐volume residual disease (SVRD) < 1 cm

Large‐volume residual disease (LVRD) > 1 cm probably leads to higher overall survival: Median length of compared with small‐volume residual disease (SVRD) < 1 cm (moderate certainty).

• Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after… 2022 · Cochrane Headline outcomes only
  HR 1.22 [1.13, 1.32]
  5 studies · 6000 participants
  Moderate

Large‐volume residual disease (LVRD) > 1 cm vs small‐volume residual disease (SVRD) < 1 cm

Large‐volume residual disease (LVRD) > 1 cm probably leads to higher progression‐free survival: Median length of compared with small‐volume residual disease (SVRD) < 1 cm (moderate certainty).

• Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after… 2022 · Cochrane Headline outcomes only
  HR 1.3 [1.08, 1.56]
  2 studies · 3402 participants
  Moderate

Small‐volume residual disease (SVRD) (< 1 cm) vs NMRD

It is very uncertain whether small‐volume residual disease (SVRD) (< 1 cm) changes overall survival: Median length of compared with NMRD (very low certainty).

• Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after… 2022 · Cochrane Headline outcomes only
  HR 2.09 [1.2, 3.6]
  1 study · 310 participants
  Very low

Small‐volume residual disease (SVRD) (< 1 cm) vs NMRD

• Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 322 participants
  Very low

Large‐volume residual disease (LVRD) > 1 cm vs NMRD

It is very uncertain whether large‐volume residual disease (LVRD) > 1 cm changes overall survival: Median length of compared with no macroscopic residual disease (NMRD) (very low certainty).

• Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after… 2022 · Cochrane Headline outcomes only
  HR 2.23 [1.49, 3.34]
  1 study · 343 participants
  Very low

Hormone replacement therapy (HRT) vs no HRT

Hormone replacement therapy (HRT) may leads to lower overall survival compared with no HRT (low certainty).

• Hormone replacement therapy after surgery for epithelial ovarian cancer 2020 · Cochrane Headline outcomes only
  HR 0.71 [0.54, 0.93]
  3 studies · 350 participants
  Low

Hormone replacement therapy (HRT) vs no HRT

• Hormone replacement therapy after surgery for epithelial ovarian cancer 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 75 participants
  Very low

Hormone replacement therapy (HRT) vs no HRT

Hormone replacement therapy (HRT) showed no clear difference in progression‐free survival compared with no HRT (low certainty).

• Hormone replacement therapy after surgery for epithelial ovarian cancer 2020 · Cochrane Headline outcomes only
  HR 0.76 [0.57, 1.01]
  2 studies · 275 participants
  Low

Hormone replacement therapy (HRT) vs no HRT

It is very uncertain whether hormone replacement therapy (HRT) changes incidence of breast cancer compared with no HRT (very low certainty).

• Hormone replacement therapy after surgery for epithelial ovarian cancer 2020 · Cochrane Headline outcomes only
  RR 2 [0.19, 21.59]
  2 studies · 225 participants
  Very low

Hormone replacement therapy (HRT) vs no HRT

It is very uncertain whether hormone replacement therapy (HRT) changes incidence of transient ischaemic attack compared with no HRT (very low certainty).

• Hormone replacement therapy after surgery for epithelial ovarian cancer 2020 · Cochrane Headline outcomes only
  RR 5 [0.24, 102.42]
  1 study · 150 participants
  Very low

Hormone replacement therapy (HRT) vs no HRT

It is very uncertain whether hormone replacement therapy (HRT) changes incidence of cerebrovascular accident compared with no HRT (very low certainty).

• Hormone replacement therapy after surgery for epithelial ovarian cancer 2020 · Cochrane Headline outcomes only
  RR 0.67 [0.11, 3.88]
  1 study · 150 participants
  Very low

Hormone replacement therapy (HRT) vs no HRT

It is very uncertain whether hormone replacement therapy (HRT) changes incidence of myocardial infarction compared with no HRT (very low certainty).

• Hormone replacement therapy after surgery for epithelial ovarian cancer 2020 · Cochrane Headline outcomes only
  RR 0.2 [0.01, 4.1]
  1 study · 150 participants
  Very low

Hormone replacement therapy (HRT) vs no HRT

The review found no eligible studies for this question.

• Hormone replacement therapy after surgery for epithelial ovarian cancer 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

• Adjuvant (post‐surgery) chemotherapy for early stage epithelial ovarian cancer 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1008 participants
  High

Intervention not reported

• Adjuvant (post‐surgery) chemotherapy for early stage epithelial ovarian cancer 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1170 participants
  High

Intervention not reported

• Adjuvant (post‐surgery) chemotherapy for early stage epithelial ovarian cancer 2015 · Cochrane Headline outcomes only
  no estimate extracted
  925 participants
  High